SCHEMBL2998039

SCHEMBL2998039

O=S(=O)(c1ccc(F)cc1Cl)N1CCN(c2nc(-c3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.58
L3MBTL1 Q9Y468 4/20 0.58
ALDH1A1 P00352 3/20 0.58
LMNA P02545 4/20 0.56
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPK1 P28482 5/20 0.53
USP2 O75604 1/20 0.50
RECQL P46063 1/20 0.50
HSD17B10 Q99714 1/20 0.50
AR P10275 4/20 0.43
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016755 0.96 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3015864 0.95 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3019279 0.94 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3003604 0.93 ALDH1A1 (0.57) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3009697 0.91 SMN1; SMN2 (0.53) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3650238 0.91 SMN1; SMN2 (0.54) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3005780 0.90 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3012811 0.90 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3003206 0.90 SMN1; SMN2 (0.66) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT
SCHEMBL3018423 0.89 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885L3MBTL1 1847/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.